Trial · NCT05090566
Participant flow18
How many started, completed or left each group, period by period.
1 to 18 of 18
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 1 | 2 | |
| Overall Study | STARTED | SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 2 | 6 | |
| Overall Study | STARTED | SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 3 | 10 | |
| Overall Study | STARTED | SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 3A | 10 | |
| Overall Study | STARTED | SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 4A | 6 | |
| Overall Study | STARTED | SSB, Phase 1b: Elranatamab + Lenalidomide + Dexamethasone, Dose Level 1 | 12 | |
| Overall Study | COMPLETED | SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 1 | 0 | |
| Overall Study | COMPLETED | SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 2 | 0 | |
| Overall Study | COMPLETED | SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 3 | 0 | |
| Overall Study | COMPLETED | SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 3A | 0 | |
| Overall Study | COMPLETED | SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 4A | 0 | |
| Overall Study | COMPLETED | SSB, Phase 1b: Elranatamab + Lenalidomide + Dexamethasone, Dose Level 1 | 0 | |
| Overall Study | NOT COMPLETED | SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 1 | 2 | |
| Overall Study | NOT COMPLETED | SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 2 | 6 | |
| Overall Study | NOT COMPLETED | SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 3 | 10 | |
| Overall Study | NOT COMPLETED | SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 3A | 10 | |
| Overall Study | NOT COMPLETED | SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 4A | 6 | |
| Overall Study | NOT COMPLETED | SSB, Phase 1b: Elranatamab + Lenalidomide + Dexamethasone, Dose Level 1 | 12 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05090566/flow